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Souvenaid in the management of mild
cognitive impairment: an expert consensus
opinion
Jeffrey Cummings1*, Peter Passmore2, Bernadette McGuinness2, Vincent Mok3, Christopher Chen4,
Sebastiaan Engelborghs5,6, Michael Woodward7, Sagrario Manzano8, Guillermo Garcia-Ribas9, Stefano Cappa10,
Paulo Bertolucci11 and Leung-Wing Chu12
Abstract
Background: Mild cognitive impairment (MCI) among an aging global population is a growing challenge for
healthcare providers and payers. In many cases, MCI is an ominous portent for dementia. Early and accurate
diagnosis of MCI provides a window of opportunity to improve the outcomes using a personalized care plan
including lifestyle modifications to reduce the impact of modifiable risk factors (for example, blood pressure control
and increased physical activity), cognitive training, dietary advice, and nutritional support. Souvenaid is a once-daily
drink containing a mixture of precursors and cofactors (long-chain omega-3 fatty acids, uridine, choline, B vitamins,
vitamin C, vitamin E, and selenium), which was developed to support the formation and function of neuronal
membranes and synapses. Healthcare providers, patients, and carers require expert advice about the use of
Souvenaid.
Methods: An international panel of experts was convened to review the evidence and to make recommendations
about the diagnosis and management of MCI, identification of candidates for Souvenaid, and use of Souvenaid in
real-world practice. This article provides a summary of the expert opinions and makes recommendations for clinical
practice and future research.
Summary of opinion: Early diagnosis of MCI requires the use of suitable neuropsychological tests combined with
a careful clinical history. A multimodal approach is recommended; dietary and nutritional interventions should be
considered alongside individualized lifestyle modifications. Although single-agent nutritional supplements have
failed to produce cognitive benefits for patients with MCI, a broader nutritional approach warrants consideration.
Evidence from randomized controlled trials suggests that Souvenaid should be considered as an option for some
patients with early Alzheimer’s disease (AD), including those with MCI due to AD (prodromal AD).
Conclusion: Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using
a multimodal management approach including lifestyle risk factor modification and consideration of the
multinutrient Souvenaid.
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Background
Mild cognitive impairment (MCI) is heterogeneous
but in approximately 50% of cases represents a transi-
tional state between normal aging and dementia [1,
2]. Early diagnosis of Alzheimer’s disease (AD) in the
MCI/prodromal stage presents an opportunity for in-
terventions to improve brain health or cognitive func-
tioning and to manage modifiable risk factors
implicated in disease progression [3]. The objectives
of this paper are to describe and evaluate the current
identification and management of patients with MCI
and to assess the role of Souvenaid (a multinutrient
product) in the management of the MCI population.
Since the term MCI covers a wide range of clinical
presentations, an important objective was to examine
the potential role of Souvenaid based on the evidence
that specifically defined MCI and AD subtypes. In
particular, this paper focuses on the management of
patients with MCI with underlying AD pathology
(e.g., prodromal AD or MCI due to AD).
Diet and nutritional status are recognized as im-
portant considerations in healthy brain aging and de-
mentia [4]; however, clinical trial evidence for the
effectiveness of single nutritional interventions in
MCI remains limited [5]. Randomized clinical trials of
Souvenaid have provided evidence for improvement in
memory performance in subjects with early Alzhei-
mer’s disease (AD) [6, 7], but not in those with more
advanced stages of AD [8]. More recently, European
investigators reported encouraging findings from a trial in
subjects with prodromal AD (MCI due to AD), which
showed that Souvenaid had beneficial effects on cognition
and function (Clinical Dementia Rating Scale-Sum of
Boxes [CDR-SOB] and AD Composite Score [ADCOMS])
and on hippocampal atrophy rate [9, 10]. These data raise
the possibility of considering Souvenaid as a management
option for individuals diagnosed with MCI due to AD.
This paper summarizes the key clinical issues rele-
vant to the use of Souvenaid in MCI due to AD and
is based on expert insights and consensus opinions
provided at a meeting held in July 2018 attended by
the authors and sponsored by Nutricia. The partici-
pants represented many countries, and the consensus
statement presents a global view of MCI management.
After the consensus meeting, we searched ClinicalTrials.-
gov, WHO’s International Clinical Trial Registry Platform,
and PubMed to find new clinical trials and publications
about nutritional interventions in subjects with MCI,
using the specific search terms “Alzheimer’s disease,”
“mild cognitive impairment,” “nutrition,” “Souvenaid,” and
“Fortasyn Connect.” All authors contributed to the paper
and have approved the contents.
Role of the sponsor: Nutricia paid for the meeting
room but not travel costs and did not influence the
content of the consensus meeting. No Nutricia em-
ployees are listed as authors. The authors had full editor-
ial control and made the decision to submit the final
manuscript for publication.
How do physicians identify and diagnose MCI?
Individuals with MCI show a decline in cognitive func-
tioning greater than expected for age and educational
background [11]. People with MCI or their partners and
other family members become aware and complain
about cognitive deficits, and the initial visit to the pri-
mary care physician is usually precipitated by such com-
plaints. Amnestic MCI typically affects recent episodic
memory function and may impact several other cogni-
tive domains including executive function, language, and
visuospatial skills. People with MCI are independent
with regard to the activities of daily living.
In community practice, problems with memory
commonly raise the physicians’ suspicions of MCI or
dementia [3, 12]. Primary care physicians are encour-
aged to assess the patients complaining of memory
loss or to refer these individuals with signs of MCI
for specialist memory assessment because of the high
risk of progression to dementia, most commonly AD
[13]. In general, approximately 50% of MCI are asso-
ciated with amyloid pathology, and 10–15% per year
will transition to dementia of the AD type. The esti-
mated 3-year cumulative incidence of AD-type de-
mentia for individuals presenting with prodromal AD
(International Working Group (IWG-2) criteria) is
61% [14]. On the other hand, a systematic review re-
ported reversion rates from MCI to normal cognition
of 8% in clinical-based studies and 25% in popula-
tion-based studies [15].
US and international guidelines recommend specialist
assessment using validated tests of memory and cognitive
function for individuals with signs and symptoms of mem-
ory impairment or when family members or patients ex-
press concerns about potential cognitive decline [16–19].
Patient associations also play a key role in increasing
awareness and encouraging early diagnosis of MCI.
The success of the strategies to delay the progression of
MCI to dementia depends on early and accurate identifica-
tion of people at risk of AD, including those without any
evidence of significant neurodegeneration [20]. Appropriate
assessment by the primary care physician including screen-
ing for cognitive problems is important to expedite referral
of individuals with suspected MCI to specialists, e.g., geria-
tricians, psychiatrists, or neurologists [21, 22]; however,
many patients are not referred [23] and some healthcare or-
ganizations may even discourage the use of specialists [24].
Timely referral and diagnosis of MCI can motivate individ-
uals to adhere to potentially beneficial lifestyle changes and
treatment interventions [11].
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In the early stages, MCI may be differentiated from de-
mentia by a preservation of functional independence and
the absence of significant impairment in social or occu-
pational functions [25]; however, the precise boundary
remains elusive and there is a seamless progression from
MCI to mild dementia. Further research is advocated to
improve the accuracy and utility of assessment tools,
such as activity of daily living (ADL) scales, and to refine
screening tests at each step of the pathway to diagnosis.
There is a need to improve early diagnosis of MCI
allowing appropriate interventions designed to improve
patient or caregiver outcomes [25].
The IWG-2 criteria define, in the context of research,
prodromal AD as patients with episodic memory impair-
ment (in most cases) and a positive cerebrospinal fluid
amyloid beta (Aβ) and tau biomarker test or a positive
amyloid beta-protein (Aβ) positron emission tomog-
raphy (PET) scan [20, 25, 26]. In the National Institute
on Aging-Alzheimer’s Association criteria, among pa-
tients meeting the core clinical criteria for MCI due to
dementia, the highest likelihood of underlying AD path-
ology is associated with positive biomarkers for both Aβ
and neuronal injury, while an intermediate risk is associ-
ated with either a positive biomarker reflecting Aβ de-
position with an unavailable biomarker of neuronal
injury or a positive biomarker reflecting neuronal injury
with an unavailable biomarker of Aβ [19]. Further re-
search is important to improve early diagnosis and to fa-
cilitate more individualized management [26].
Individuals with suspected MCI should have a com-
prehensive medical history and physical examination to
distinguish between MCI and normal aging or dementia
and to identify individuals with potentially reversible (or
irreversible) MCI caused by other underlying conditions
[25]. Neuropsychiatric assessment is advocated by some
experts because apathy, depression, and agitation are
often the early symptoms of MCI [27]. An evaluation
may also identify patients in early phases of non-AD
conditions such as frontotemporal dementia and demen-
tia with Lewy bodies.
Cognitive function assessments are recommended at
baseline and follow-up visits [25, 28, 29]; however, the
utility of available tools may be limited because many
practitioners lack familiarity with them and most have ad-
ministration times incompatible with the short visit times
of many busy practices. Additional research is needed to
harmonize neuropsychological tests for use in different
languages [26]. Furthermore, the sensitivity of such instru-
ments to detect MCI may be lower than that to detect de-
mentia [28]. Available screening instruments are not fully
appropriate for MCI assessment because they do not allow
a precise quantitative definition of domain-specific impair-
ment, for example, in episodic memory, with reference to
an age- and education-matched population.
While brief screening tools are appropriate in general
practice, at a specialist level, neuropsychological assess-
ment is required. Neuropsychological tests provide valu-
able objective information; they can reinforce but never
supplant clinical judgment and communication with the
patient. The patient’s clinical history is required to identify
the presence of cognitive complaints, elicited from the in-
dividual, family member, or colleague. A detailed clinical
history is essential to reflect inter-personal changes, spe-
cifically considering the individual’s behavior and social
cognition before MCI emerged. Monitoring the changes
in cognitive function, memory complaints, functional abil-
ities, and personality over time is essential, and collecting
a relevant family history may contribute additional im-
portant information.
Expert opinion:
 Early diagnosis of MCI requires the use of suitable
neuropsychological tests combined with a careful
clinical history. Physicians should explore the
clinical history because it provides important
information about the changes in individual patients,
which may alert them to the emerging cognitive
impairment even when an objective screening test is
normal.
 Biomarkers may be used to diagnose prodromal AD
in patients with MCI.
Current management of MCI
Expert reports have concluded that some medical, life-
style, psychosocial, and nutritional interventions may
prevent or delay the progression from MCI to dementia
[3, 30]; however, evidence is not robust for many inter-
ventions, and no significant benefits have been shown
with pharmacologic therapies such as cholinesterase in-
hibitors and memantine [16, 30, 31]. The Lancet Com-
mission on Dementia Prevention suggested that 21.7% of
dementia cases progressing from MCI are potentially
preventable by eliminating poor diets, diabetes, and
neuropsychiatric symptoms [3]. Attention to modifiable
risk factors is therefore the first step for patients diag-
nosed with MCI [3]. Cognitive training, blood pressure
management in people with hypertension, and increased
physical activity should be encouraged to prevent, delay,
or slow down the progression of MCI [30]. The most
compelling data are for the role of exercise in reducing
the risk of dementia [32, 33]. Table 1 summarizes a
range of interventions that may reduce the risk of
MCI and progression to dementia, and indicates,
based on the expert opinion of the authors, the
strength of the evidence supporting specific recom-
mendations [3, 4, 9, 32, 34–46].
National guidelines provide generally consistent rec-
ommendations for the management of MCI [16, 17, 47].
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Pharmacologic interventions with AD drugs are gener-
ally not recommended for patients with MCI but may be
considered if there is biomarker evidence of AD, al-
though this opinion is based on limited clinical trial
evidence [48]. Changes to lifestyle and diet are encour-
aged, with the proviso that benefits may be modest
[49]. Epidemiological studies have shown an associ-
ation between diets with high antioxidant content,
such as the Mediterranean diet, and a decreased risk
of dementia [50], MCI [51], and cognitive decline
[52–56] in older adults. The evidence also suggests
that multimodal intervention in lifestyle risk factors is
more appropriate than focusing on single parameters
[56, 57]; single nutritional supplements are not rec-
ommended because of insufficient evidence of clinical
benefit [5].
Expert opinion:
 A multimodal approach is recommended; dietary
and nutritional interventions should be considered
alongside individualized lifestyle modifications.
 Pharmacologic therapy, except for the treatment of
depression or other neuropsychiatric symptoms, is
usually not appropriate for patients diagnosed with
MCI.
Rationale for nutritional interventions
The association between diet, nutritional status, and
healthy brain aging has provided a rationale for the inves-
tigation of supplements to improve cognitive function in
patients with MCI or AD [4, 58]. Single-agent nutri-
ent supplements tested include vitamin E [59], vita-
min C [60], B vitamins [61–63], vitamin D [64],
flavonoids [65], carotenoids [65, 66], and omega-3
fatty acids [67]. Based on the existing trials, however,
there is insufficient evidence to support the use of
single-agent nutrients to modify the course of cogni-
tive decline in patients with MCI [5]. The body of
evidence showing the role of dietary and nutritional fac-
tors in MCI and AD is constantly evolving and has been
reviewed extensively in recent papers [68–70]. Despite the
failure of numerous studies to show benefits for single-
agent nutrient supplements [5], there are compelling rea-
sons to consider a nutritional approach in conjunction
with lifestyle interventions for the management of MCI
[71], for example, to enhance the supply of precursors re-
quired to make neuronal membranes and synapses [72].
The neuronal membranes are composed of a phospho-
lipid bilayer containing cholesterol and other lipids [73,
74]. Changes in the composition of these lipids and
phospholipids are associated with several neurological
Table 1 Lifestyle interventions recommended for MCI based on expert opinion
Intervention Recommendation Degree of confidence*
Medical • Ensure blood pressure is optimal [34] +++
• Ensure body mass index (BMI) is optimal [35] ++
• Ensure cholesterol level is optimal [36] +
• Ensure no undiagnosed diabetes or if diabetic ensure control is optimal for age [37] +
• Review medicines and assess for anticholinergic burden [38] +
• Ensure hearing loss is addressed [3] +
• Adopt practices to avoid head injury (use helmets, avoid unprotected contact sports) [39]
Lifestyle • Advise smoking reduction and cessation support [40] +++
• Advise limiting alcohol intake in line with currently accepted guidelines [41] ++
• Encourage physical activity and exercise [32, 33, 42] +++
• Protect against head injury [39] +
• Encourage brain fitness activities and social connectedness
• Promote good sleep patterns and adequate sleep time
Psychosocial • Adequately treat depression and anxiety [43] +++
• Advise on methods of cognitive training [44] ++
• Recommend opportunities for increasing social engagement [45] +
• Reduce stress
Nutritional • Advise on dietary principles around maintaining general health [4] ++
• Encourage adherence to diets with some evidence of benefit, such as Mediterranean, MIND, and DASH [46] +++
• Recommend evidence-based nutritional supplements, such as Souvenaid, are considered [9] +++
*Degree of confidence is based on an expert assessment of published evidence and personal experience, rather than a formal, systematic, evidence-based review:
+++, high degree of confidence with strong supporting evidence from randomized controlled trials; ++, good degree of confidence with supporting evidence; +,
fair degree of confidence with some supporting evidence
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and psychiatric diseases [75]. There is a growing consen-
sus on changed phospholipid profiles in patients with
AD [76], reflecting disturbed phospholipid metabolism
[77], which occurs early in the AD process [78, 79].
Phospholipids are affected by several of the lifestyle in-
terventions recommended in the management of MCI,
including exercise [80], smoking cessation [81], sleep
quality [82], and dietary modification [83]. The reported
benefits of combining multimodal lifestyle interventions
[56, 57] could be mediated at least in part by cumulative
effects on normalizing phospholipid metabolism. By im-
proving phospholipid metabolism, lifestyle interventions
may help to preserve neuronal functions and maintain
cognitive performance. Evidence suggests that key nutri-
ents required for phospholipid synthesis are lower in the
blood and cerebrospinal fluid of patients with MCI [84]
and such nutritional deficiencies may impair the brain’s
ability to maintain neuronal functions.
The metabolic pathway responsible for producing
brain phospholipids can be positively influenced by sup-
plying a combination of nutritional precursors and co-
factors (reviewed in Wurtman et al. [85]). Nutrients
appear to act synergistically, which suggests that a multi-
nutrient approach could be more effective than supple-
mentation with a single nutrient [71].
Several studies have shown that nutrient intervention
can increase plasma levels of nutrients involved in
phospholipid synthesis, but most failed to demonstrate
clinical benefits [86–96]. More beneficial effects may be
achieved by addressing the complete specific nutritional
requirement for phospholipid synthesis, including
phospholipid precursors, nutritional cofactors, and
antioxidants.
Expert opinion:
 Although single-agent nutritional supplements have
failed to produce cognitive benefits for patients with
MCI, a broader nutritional approach warrants
consideration.
Clinical trials of Souvenaid
Souvenaid is a once-daily drink containing a mixture of
precursors and cofactors (long-chain omega-3 fatty
acids, uridine, choline, B vitamins, vitamin C, vitamin E,
and selenium) necessary for the formation and function
of neuronal membranes and synapses [71].
The first clinical trials of Souvenaid (Table 2) showed
encouraging effects on memory performance in patients
with mild AD dementia. Souvenaid was associated with
a statistically significant improvement in memory per-
formance in patients with mild and very mild AD de-
mentia, observed over 12 weeks in Souvenir I and 24
weeks in Souvenir II [6, 7], and patients continued to ex-
hibit improved memory for up to 48 weeks [97]. Another
trial in patients with mild-moderate AD dementia
showed that Souvenaid could be taken safely with stand-
ard AD drugs; however, no significant cognitive im-
provements were demonstrated [8]. These preliminary
data suggested that the benefits of Souvenaid were most
likely to be seen at the early end of the AD spectrum,
and subsequently, an independent trial group (LipiDi-
Diet) designed a trial in patients with MCI due to AD
(prodromal AD) [9].
In 2009, the European LipiDiDiet Group started a 24-
month randomized, controlled, double-blind, parallel-
group, multicenter trial in patients with prodromal AD
[9]. Participants were randomly assigned (1.1) to active
product (125 ml once a day Souvenaid) or control prod-
uct and were not receiving cholinesterase inhibitors at
baseline. The primary endpoint was a change in a
neuropsychological test battery (NTB; composite z-
score based on the Consortium to Establish a Registry
for Alzheimer’s Disease [CERAD] 10-word list learning
immediate recall, CERAD 10-word delayed recall,
CERAD 10-word recognition, category fluency, and let-
ter digit substitution test). Although the intervention
had no significant effect on the primary endpoint over
2 years, cognitive decline in this trial population was
much lower than expected in both the treatment and
the placebo groups; therefore, the primary endpoint
was inadequately powered. The LipiDiDiet trial showed
significant differences in secondary endpoints. Signifi-
cant benefits were reported for Souvenaid in the CDR-
SOB and ADCOMS [9, 10]. In addition, a per-protocol
analysis, which excluded patients with major protocol
violations (most commonly, failure to comply with
study product intake), showed a benefit in episodic
memory (three-item memory composite z-score); this
was not significant in the intention-to-treat analysis.
Brain imaging with MRI showed significant reduction
of hippocampal atrophy and less expansion of ventricu-
lar volume in patients taking Souvenaid.
Taken together, the 4 randomized controlled trials
including a total of 1332 patients with prodromal AD
or mild-moderate AD dementia (Table 2) showed that
Souvenaid was well tolerated [6–9]. Only 1 of these
trials (LipiDiDiet trial) specifically studied the use of
Souvenaid in MCI due to AD (prodromal AD). Ad-
verse events reported in the LipiDiDiet trial are
shown in Additional file 1: Table S1.
An effect size analysis was done to see whether the ef-
fects of Souvenaid are clinically detectable in patients
with early AD [98]. Effect sizes > 0.2 are considered large
enough to be clinically meaningful [99]. The calculated
effect sizes (Cohen’s d statistic) were 0.21 (95% confi-
dence intervals − 0.06, 0.49) for the primary outcome in
Souvenir II (NTB memory z-score) and 0.20 (0.10, 0.34)
for the co-primary outcome of Souvenir I (Wechsler
Cummings et al. Alzheimer's Research & Therapy           (2019) 11:73 Page 5 of 11
Ta
b
le
2
Su
m
m
ar
y
of
ra
nd
om
iz
ed
cl
in
ic
al
tr
ia
ls
of
So
uv
en
ai
d
in
pa
tie
nt
s
w
ith
pr
od
ro
m
al
A
D
(M
C
Id
ue
to
A
D
),
m
ild
A
D
de
m
en
tia
,a
nd
m
ild
-m
od
er
at
e
A
D
de
m
en
tia
Po
pu
la
tio
n
Pr
od
ro
m
al
A
D
a
M
ild
A
D
de
m
en
tia
b
M
ild
A
D
de
m
en
tia
c
M
ild
-m
od
er
at
e
A
D
de
m
en
tia
d
Re
fe
re
nc
e
Li
pi
D
iD
ie
t
[9
]
So
uv
en
ir
II
[7
,9
7]
So
uv
en
ir
I[
6]
S-
C
on
ne
ct
[8
]
A
D
dr
ug
us
e
N
o
N
o
N
o
Ye
s
In
te
rv
en
tio
n
du
ra
tio
n
24
m
on
th
s
24
w
ee
ks
(+
24
-w
ee
k
ex
te
ns
io
n)
12
w
ee
ks
(+
12
-w
ee
k
ex
te
ns
io
n)
24
w
ee
ks
N
o.
of
pa
tie
nt
s
ra
nd
om
iz
ed
31
1
25
9
22
5
52
7
C
ou
nt
ry
Fi
nl
an
d,
G
er
m
an
y,
Th
e
N
et
he
rla
nd
s,
Sw
ed
en
Th
e
N
et
he
rla
nd
s,
G
er
m
an
y,
Be
lg
iu
m
,S
pa
in
,
Ita
ly
,F
ra
nc
e
Th
e
N
et
he
rla
nd
s,
G
er
m
an
y,
Be
lg
iu
m
,
U
K,
U
SA
U
SA
Et
hn
ic
or
ig
in
99
%
W
hi
te
N
ot
st
at
ed
N
ot
st
at
ed
94
%
W
hi
te
M
ea
n
ag
e
(y
ea
rs
)
71
73
.8
73
.7
76
.7
M
al
e/
fe
m
al
e
(%
)
49
.5
/5
0.
5
51
/4
9
50
/5
0
48
/5
2
A
ve
ra
ge
M
M
SE
26
.6
25
23
.9
19
.5
Pr
im
ar
y
ou
tc
om
es
N
TB
co
m
po
si
te
sc
or
e
m
ea
su
rin
g
co
gn
iti
on
N
TB
m
em
or
y
do
m
ai
n
co
m
po
si
te
sc
or
e
W
M
S-
r
de
la
ye
d
ve
rb
al
re
ca
ll
m
ea
su
rin
g
ep
is
od
ic
m
em
or
y
M
od
ifi
ed
13
-it
em
A
D
A
S-
co
g
as
se
ss
in
g
co
gn
iti
on
11
-it
em
A
D
A
S-
co
g
m
ea
su
rin
g
co
gn
iti
on
Se
co
nd
ar
y
ou
tc
om
es
C
D
R-
SO
B
Br
ai
n
vo
lu
m
es
ba
se
d
on
M
RI
(3
D
T1
-w
ei
gh
te
d
an
at
om
ic
al
sc
an
s
of
to
ta
lh
ip
po
ca
m
pa
l,
w
ho
le
br
ai
n,
an
d
ve
nt
ric
ul
ar
vo
lu
m
es
Pr
og
re
ss
io
n
to
de
m
en
tia
N
ut
rit
io
na
lb
lo
od
pa
ra
m
et
er
s
N
TB
ex
ec
ut
iv
e
fu
nc
tio
n
do
m
ai
n
N
TB
to
ta
lc
om
po
si
te
sc
or
e
D
A
D
EE
G
N
ut
rit
io
na
lb
lo
od
pa
ra
m
et
er
s
A
D
C
S-
A
D
L
W
M
S-
r
im
m
ed
ia
te
ve
rb
al
re
ca
ll
C
IB
IC
-p
lu
s
N
PI
Q
O
L-
A
D
N
ut
rit
io
na
lb
lo
od
pa
ra
m
et
er
s
C
og
ni
tiv
e
te
st
ba
tt
er
y
(D
ig
it
Sp
an
-W
M
S,
co
nc
ep
t
sh
ift
in
g
te
st
,l
et
te
r
di
gi
t
su
bs
tit
ut
io
n
te
st
,a
nd
ca
te
go
ry
flu
en
cy
)
A
D
C
S-
A
D
L
C
D
R-
SO
B
N
ut
rit
io
na
lb
lo
od
pa
ra
m
et
er
s
A
D
A
S-
co
g
A
lz
he
im
er
’s
D
is
ea
se
A
ss
es
sm
en
t
Sc
al
e-
co
gn
iti
ve
su
bs
ca
le
,A
D
CS
-A
D
L
A
lz
he
im
er
’s
D
is
ea
se
C
o-
op
er
at
iv
e
St
ud
y-
A
ct
iv
iti
es
of
D
ai
ly
Li
vi
ng
,C
D
R-
SO
B
C
lin
ic
al
D
em
en
tia
Ra
tin
g
Su
m
of
Bo
xe
s,
CI
BI
C-
pl
us
C
lin
ic
ia
n
In
te
rv
ie
w
-B
as
ed
Im
pr
es
si
on
of
C
ha
ng
e
pl
us
C
ar
eg
iv
er
In
pu
t,
CS
F
ce
re
br
os
pi
na
lf
lu
id
,D
A
D
D
is
ab
ili
ty
A
ss
es
sm
en
t
fo
r
D
em
en
tia
Sc
al
e,
EE
G
el
ec
tr
oe
nc
ep
ha
lo
gr
ap
hy
,M
EG
m
ag
ne
to
en
ce
ph
al
og
ra
ph
y,
M
M
SE
M
in
i-M
en
ta
l
St
at
e
Ex
am
in
at
io
n,
M
RI
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g,
N
PI
ne
ur
op
sy
ch
ia
tr
ic
in
ve
nt
or
y,
N
TB
ne
ur
op
sy
ch
ol
og
ic
al
te
st
ba
tt
er
y,
Q
O
L-
A
D
Q
ua
lit
y
of
Li
fe
in
A
lz
he
im
er
’s
D
is
ea
se
,W
M
S-
r
W
ec
hs
le
r
M
em
or
y
Sc
al
e-
re
vi
se
d
a P
ro
dr
om
al
A
D
as
de
fin
ed
by
ep
is
od
ic
m
em
or
y
di
so
rd
er
(p
er
fo
rm
an
ce
be
lo
w
on
e
st
an
da
rd
de
vi
at
io
n
on
tw
o
of
ei
gh
t
co
gn
iti
ve
te
st
s
[a
t
le
as
t
on
e
on
m
em
or
y]
)
an
d
ev
id
en
ce
fo
r
un
de
rly
in
g
A
D
pa
th
ol
og
y
ba
se
d
on
po
si
tiv
e
fin
di
ng
s
fr
om
at
le
as
t
on
e
of
th
e
fo
llo
w
in
g
di
ag
no
st
ic
te
st
s:
C
SF
,M
RI
,a
nd
1
8
F
flu
or
od
eo
xy
gl
uc
os
e
(1
8
F-
FD
G
)
PE
T
an
al
ys
is
b
Pr
ob
ab
le
A
D
ac
co
rd
in
g
to
th
e
N
at
io
na
lI
ns
tit
ut
e
of
N
eu
ro
lo
gi
ca
la
nd
C
om
m
un
ic
at
iv
e
D
is
or
de
rs
an
d
St
ro
ke
an
d
th
e
A
lz
he
im
er
’s
D
is
ea
se
an
d
Re
la
te
d
D
is
or
de
rs
A
ss
oc
ia
tio
n
(N
IN
C
D
S-
A
D
RD
A
)
cr
ite
ria
,a
n
M
M
SE
sc
or
e
of
≥
20
,a
nd
re
ce
nt
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g
(M
RI
)
or
co
m
pu
te
d
to
m
og
ra
ph
y
(C
T)
sc
an
ha
d
sh
ow
n
no
ev
id
en
ce
of
an
y
ot
he
r
po
te
nt
ia
lc
au
se
s
of
de
m
en
tia
c P
ro
ba
bl
e
A
D
ac
co
rd
in
g
to
th
e
N
IN
C
D
S-
A
D
RD
A
cr
ite
ria
,a
M
M
SE
sc
or
e
of
20
–2
6,
an
d
a
re
ce
nt
M
RI
or
C
T
sc
an
co
m
pa
tib
le
w
ith
A
D
d
Pr
ob
ab
le
A
D
ac
co
rd
in
g
to
th
e
N
IN
C
D
S-
A
D
RD
A
cr
ite
ria
,a
M
M
SE
sc
or
e
be
tw
ee
n
14
an
d
24
in
cl
us
iv
e,
an
d
us
e
of
U
S
Fo
od
an
d
D
ru
g
A
dm
in
is
tr
at
io
n-
ap
pr
ov
ed
A
D
m
ed
ic
at
io
n
on
a
st
ab
le
do
se
fo
r
at
le
as
t
4
m
on
th
s
pr
io
r
to
ba
se
lin
e
Cummings et al. Alzheimer's Research & Therapy           (2019) 11:73 Page 6 of 11
Memory Scale delayed recall). The number needed to
treat (NNT) values for Souvenaid were 6 for Wechsler
Memory Scale-revised (WMS-r) delayed memory (> 0)
in Souvenir I, 9 for NTB memory (≥ 0.3), and 21 for
NTB memory (≥ 0.0) in Souvenir II. The low NNT and
high number needed to harm (NNH) indicated a favor-
able harm-to-benefit ratio for Souvenaid in patients with
mild AD dementia [98]. Additional data from the LipiDi-
Diet trial showed effect sizes of 0.17 for the primary
NTB endpoint and 0.33 for the secondary CDR-SOB
endpoint, with NNT values of 10 and 6, respectively,
and high NNH values [9]. Effect size analyses help to in-
form the discussion about whether interventional effects
of Souvenaid may be considered clinically meaningful
and suggest that benefits are greatest when using Souve-
naid early in the course of AD.
A meta-analysis of published clinical trials showed
Souvenaid was associated with improvements in verbal
recall in patients at early stages of AD dementia. Souve-
naid had no detected beneficial effects on functional
ability, behavior, or global clinical change over the broad
spectrum of AD [100]. However, this meta-analysis was
not based on individual patient data and did not include
data from the LipiDiDiet trial.
The data from randomized controlled trials corrobor-
ate the putative mode of action of Souvenaid, i.e.,
improving the supply of nutrients required for phospho-
lipid metabolism and to support neuronal structure and
function [85]. Measurements of nutritional biomarkers
showed increased nutrient levels [9, 97] and phosphat-
idylcholine-docosahexaenoic acid levels [76] in the
bloodstream and increased choline levels and markers of
phospholipid synthesis in the brain revealed by magnetic
resonance spectroscopy [101]. Furthermore, electroen-
cephalography showed improved functional network
connectivity in patients with early AD [102]. An explora-
tory study, with a small sample size and unbalanced
study groups, did not show any treatment effects using
the novel technique of magnetoencephalography [103].
Brain imaging did show a reduced brain atrophy rate in
patients with prodromal AD, suggesting a potential ef-
fect on the disease process [9]. A post hoc analysis of
data from the LipiDiDiet trial showed a correlation be-
tween the preservation of hippocampal volume and
memory and CDR-SB [104]. Changes in biomarkers, par-
ticularly in hippocampal volume, support the proposed
mode of action of Souvenaid, but the relation between
the biomarkers and clinical outcomes remains hypothet-
ical. Currently, there is insufficient evidence to show that
nutritional biomarkers could be used to indicate the effi-
cacy of Souvenaid. Further clinical trial evidence may
support the hypotheses generated.
Real-world data and patient experience programs have
also reported benefits for Souvenaid in patients with
cognitive impairment and mild AD, including increased
motivation and social engagement, improved energy
levels, physical and mental resilience, and improvements
in mood, cognition, and memory associated with a re-
turn to functional tasks and hobbies [105–110]. One
study showed that Souvenaid was effective on behavioral
and functional deficits [105], while another reported im-
provements in depression, anxiety, and apathy [109].
Furthermore, caregivers reported benefits in the Subject-
ive Changing Scale (SCS) in patients with MCI at high
risk of progression to AD taking Souvenaid [110]. It is
important to note that data from these studies are not as
strong as the data from randomized controlled trials.
Expert opinion:
 Evidence from randomized controlled trials suggests
that Souvenaid should be considered as a
management option for some patients with early
AD, including MCI.
Who may benefit from Souvenaid?
Randomized controlled trials investigated Souvenaid
across a spectrum of patients with AD, ranging from
prodromal AD to mild-moderate AD dementia, and the
data showed that the benefits are greater when the prod-
uct is used early in the disease course. In the LipidiDiet
study, pre-specified subgroup analyses showed the bene-
fits of Souvenaid on cognition, memory, and hippocam-
pal volume were greater among patients with very mild
disease (MMSE ≥ 26) [9]. An exploratory analysis of
these data showed that the effect of Souvenaid on CDR-
SOB increased with higher baseline MMSE scores. In
patients with a diagnosis of dementia, randomized con-
trolled trials of Souvenaid showed significant benefits in
mild AD [6, 7], but not in drug-treated mild-moderate
AD dementia (MMSE 14–24) [8].
The low NNT and excellent NNH values together
with high rates of long-term product adherence show
that Souvenaid is a viable option for use in early-
stage disease, including MCI due to AD. Biomarkers
should be used to support the diagnosis of MCI due
to AD (prodromal AD) because the only randomized
controlled trial data showing clinical benefit were ob-
tained in this population; subjects in the LipiDiDiet
trial had to have evidence for the underlying AD
pathology based on the positive findings from at least
one diagnostic test (CSF, MRI, and 18F-FDG PET) [9].
No studies are available on the effects of Souvenaid
in MCI patients with a different diagnostic type. At
present, there is insufficient evidence to show that
biomarkers could be used at an individual level to see
if patients are benefiting from Souvenaid.
Expert opinion:
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 Souvenaid should be considered as an option for
patients with a diagnosis of MCI due to AD
pathology (prodromal AD) or mild AD dementia.
 Souvenaid is not recommended for patients with
moderate or advanced AD dementia.
For how long may Souvenaid be taken?
Based on the findings of the LipiDiDiet trial [9], patients
with MCI due to AD should expect to take Souvenaid
for at least 2 years. They may continue to take Souvenaid
every day until the physician determines that there is no
evidence of benefit, intolerance develops, or patients
progress to moderate AD. The benefit can be assessed at
each clinic visit using objective tools to assess cognitive
functions and subjective reports from the patient and
carers. Such information should be considered in the
context of the patient’s clinical history.
Souvenaid is well tolerated; however, any features of poor
tolerability by individual patients could disrupt adherence
and lead to discontinuation. In the LipiDiDiet trial, reported
adverse events such as headache and diarrhea were similar
in Souvenaid and control groups, and dropout rates due to
adverse events were not significantly different between the
groups (6% vs 4%, respectively; p = 0.437).
It is important to inform patients about the need to
adhere to long-term daily intake because the clinical trial
data show that the greatest clinical benefits were seen
among patients taking the product per protocol [7]. Pa-
tients should also be informed about the financial impli-
cations of using Souvenaid, especially when they are self-
funding, as most will be.
When starting Souvenaid, patients and their caregivers
should be given realistic advice about their expected dis-
ease course. The risk of progression to AD dementia is
significantly higher among individuals with prodromal
AD (IWG-2 criteria) compared with those without pro-
dromal AD (61% vs 22% progression at 3 years; hazard
ratio 4.0 [95% confidence intervals 3.0–5.2]) [14]. Fur-
thermore, progression to AD is more likely in patients
with prodromal AD than in those with other forms of
MCI [111]. The LipiDiDiet trial continues to monitor
the progression rates in subjects continuing to take Sou-
venaid compared with controls; however, currently,
there is not enough evidence to conclude that Souvenaid
decreases the rate of progression from MCI to dementia.
Patients progressing from MCI to mild AD dementia
may continue to benefit from Souvenaid [6, 7]. Continu-
ing Souvenaid is not recommended for patients progres-
sing from early to moderate or severe AD dementia [8].
Expert opinion:
 Patients with MCI should take Souvenaid for 2 years
or longer if there is evidence of continuing benefit.
 Souvenaid should be stopped if intolerance develops,
the patient is no longer benefitting, or they progress
to moderate-severe AD.
Implications for practice, policy, and/or research
Early identification of individuals at risk of progression from
MCI to AD dementia is crucial to facilitate patient manage-
ment at a time when pathological changes and clinical defi-
cits are not yet severe [20]. Primary care physicians have an
important role to play in referring individuals with suspected
MCI for specialist assessment. Currently, however, there are
no treatment options recommended in national guidelines to
slow or reverse the progression of MCI to dementia. Data
suggest that management of patients with a diagnosis of
MCI requires a multimodal approach involving lifestyle
changes to reduce the effects of modifiable risk factors (hear-
ing loss, obesity, hypertension, smoking, depression, physical
inactivity, social isolation, and diabetes mellitus) [3] and to
promote healthy nutrition [4, 58].
Encouraging patients to adopt a healthy lifestyle and diet
to support cognitive function is an important first step in
the management of patients with MCI [4, 58]. In addition,
patients should be provided with information about the
multinutrient product Souvenaid, which may be considered
as an option for patients with MCI; however, it is important
to make patients aware that clinical trial data were obtained
in patients with a diagnosis of MCI with AD pathology.
Conclusion
The consensus opinion of the expert panel is summa-
rized in Table 3. Additional research is required to refine
the identification of patients most likely to benefit from
Souvenaid and to assess response and clinical benefit
during long-term management.
Table 3 Summary of expert opinion on MCI
• Early diagnosis of MCI requires the use of suitable neuropsychological
tests combined with a careful clinical history. Physicians should explore
the clinical history because it provides important information about
the changes in individual patients, which may alert them to the
emerging cognitive impairment even when an objective screening test
is normal.
• A multimodal approach is recommended; dietary and nutritional
interventions should be considered alongside individualized lifestyle
modifications. Pharmacologic therapy, except for the treatment of
depression or other neuropsychiatric symptoms, is usually not
appropriate for patients diagnosed with MCI.
• Although single-agent nutritional supplements have failed to produce
cognitive benefits for patients with MCI, a broader nutritional approach
warrants consideration.
• Evidence from randomized controlled trials suggests that Souvenaid
should be considered as a management option for patients with early
AD, including MCI.
• Souvenaid should be considered as an option for patients with a
diagnosis of MCI due to AD (prodromal AD) or mild AD dementia.
Souvenaid is not recommended for patients with moderate or
advanced AD dementia
• Patients with MCI should take Souvenaid for 2 years or longer if there
is evidence of continuing benefit.
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Additional file
Additional file 1: Table S1. LipiDiDiet trial adverse events in
participants randomly assigned to Souvenaid or control [9]. (DOCX 13 kb)
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